表柔比星注射液联合甲地孕酮片对子宫内膜癌肿瘤标志物及相关蛋白的影响

目的:探讨表柔比星注射液联合甲地孕酮片对子宫内膜癌患者肿瘤标志物及相关蛋白的影响。方法:收集本院子宫内膜癌患者90例,依据患者对治疗方案的选择分为观察组(50例)和对照组(40例),对照组口服甲地孕酮片治疗,观察组在对照组治疗基础上静脉滴注表柔比星,比较治疗前后两组患者性激素、肿瘤标志物及相关蛋白水平的变化。结果:治疗结束后两组患者睾酮水平变化不明显(P>0.05),卵泡刺激素、孕酮、雌二醇、黄体生成素水平显著降低,人附睾上皮分泌蛋白4、CEA、糖类抗原125水平显著降低,肿瘤相关蛋白PCNA、Bcl-2水平降低,Bax蛋白水平升高(均P<0.05),且观察组变化幅度均大于对照组(均P<0.05);观察组治疗总有效率(82.0%)高于对照组(62.5%),不良反应发生率(30.0%)低于对照组(57.5%)(均P<0.05)。结论:表柔比星注射液联合甲地孕酮片治疗子宫内膜癌效果更加显著,可更好地改善患者生存质量,降低不良反应,具有一定的临床应用价值。

Effect of epirubicin injection combined with megestrol acetate tablets on the levels of tumor markers and related protein of women with endometrial carcinoma

Objective:To investigate the effect of epirubicin injection combined with megestrol tablets on the levels of tumor markers and related proteins of women with endometrial carcinoma.Methods:90 patients with endometrial cancer were enrolled and were divided into observation group(50 cases)and control group(40 cases)according to their choice of treatment plan.The patients in the control group were treated with megestrol tablets orally,and the patients in the observation group were given epirubicin injection combined with megestrol tablets.The changes of the sex hormones levels,and tumor markers and related protein levels of the patients were compared between the two groups before and after treatment.Results:At the end of treatment,there was no significant change in the testosterone level of the patients in the two groups(P>0.05),but the levels of follicle stimulating hormone,progesterone,estradiol,luteinized hormone,human epididymal epithelial secreted protein 4,CEA,carbohydrate antigen 125,tumor-related protein PCNA,and Bcl-2 had decreased significantly,and the levels of level of Bax protein had increased significantly,the changes of the patients in the observation group was significant more than that those of the patients in the control group(all P<0.05).The total effective rate of the patients in the observation group(82.0%)was significant higher than that(62.5%)of the patients in the control group,but the incidence of adverse reactions of the patients in the observation group(30.0%)was significant lower than that(57.5%)of the patients in the control group(all P<0.05).Conclusion:Epirubicin injection combined with megestrol tablets for treating patients with endometrial cancer has high effect,which can effectively improve the quality of life and reduce the adverse reaction of patients,so it has certain clinical application value.